Less Ads, More Data, More Tools Register for FREE

Pin to quick picksZotefoams Plc Regulatory News (ZTF)

Share Price Information for Zotefoams Plc (ZTF)

Share Price is delayed by 15 minutes
Get Live Data
442.00    -4.00 (-0.90%)
Bid:
442.00
Ask:
446.50
Spread: 4.50 (1.018%)
Market Cap: £217.38m
ZTF Live PriceLast checked at - London Stock Exchange

Intraday Zotefoams Plc Share Chart

Trading Statement

14 Jan 2016 07:00

RNS Number : 8085L
Zotefoams PLC
14 January 2016
 

Zotefoams plc

("Zotefoams" or "the Company")

 

Trading Update

 

14 January 2016 - Zotefoams, a world leader in cellular material technology, today provides a trading update following the Company's financial year end on 31 December 2015.

 

The Board expects to report an outcome in line with management expectations for the year ended 31 December 2015. Sales1 in the second half of 2015 grew by around 13% compared to the equivalent period in 2014. This is expected to deliver sales growth of approximately 10% for the financial year as a whole.

Polyolefin sales value grew by around 7% for the year, with a 10% growth in volume offset by adverse foreign exchange rates. High-Performance Products sales grew by approximately 24%. In MuCell Extrusion LLC, our technology licensing business, we have achieved a lower average conversion cost to customers which makes adoption of the technology more attractive to customers. During the year we shipped equipment to convert 36 extrusion lines (2014: 20), increasing our overall installed base at customers by 69% to 88 units.

In Walton, Kentucky, USA, we are investing in global capacity to support future sales growth. A delay in the supply of a major piece of equipment means that the commencement of manufacturing from this investment is now expected to be approximately four months later than originally planned. We do not, however, anticipate any adverse impact on our ability to meet our growth forecast due to operational efficiency improvements achieved in Croydon, UK.

As detailed in the announcement on 24 November 2015, Gary McGrath has joined the Board as Finance Director Designate and will be formally appointed Finance Director on 1 February 2016. Clifford Hurst will work with Gary to complete the handover of this role, retiring from the Board and the Company in advance of the AGM in May 2016, as previously stated.

The Board expects to announce preliminary results for the year ended 31 December 2015 on Tuesday 15 March, 2016.

 

Enquiries:

Zotefoams plc

0208-664-1600

David Stirling, Managing Director

Clifford Hurst, Finance Director

FTI Consulting

0203-727-1000

Victoria Foster Mitchell

Simon Conway

 

 

About Zotefoams plc

Zotefoams plc (LSE - ZTF) is a world leader in cellular material technology. Using a unique manufacturing process with environmentally friendly nitrogen expansion, Zotefoams produces lightweight foams in Croydon, UK and Kentucky, USA for diverse markets worldwide through its global sales force. Zotefoams also owns and licenses patented MuCell® microcellular foam technology from a base in Massachusetts, USA to customers worldwide and sells T-Tubes® advanced insulation systems made from its patented ZOTEK® fluoropolymer foams.

 

www.zotefoams.com

 

ZOTEK® is a registered trademark of Zotefoams plc. MuCell® is a registered trademark of Trexel Inc. T-Tubes® is a registered trademark of UFP Technologies Inc.

 

 

1 Sales made by joint ventures as well as those made by Zotefoams plc and its subsidiaries.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTBJMRTMBABBBF
Date   Source Headline
20th Jul 20224:36 pmRNSPrice Monitoring Extension
12th Jul 202212:39 pmRNSDirector/PDMR Shareholding
8th Jul 20227:00 amRNSNotice of Results
30th Jun 20224:52 pmRNSDirector/PDMR Shareholding
8th Jun 20224:40 pmRNSSecond Price Monitoring Extn
8th Jun 20224:35 pmRNSPrice Monitoring Extension
8th Jun 20228:49 amRNSDirector/PDMR Shareholding
26th May 20224:41 pmRNSSecond Price Monitoring Extn
26th May 20224:36 pmRNSPrice Monitoring Extension
25th May 20221:04 pmRNSResult of the 2022 Annual General Meeting
25th May 20227:00 amRNSTrading Update
18th May 20224:41 pmRNSSecond Price Monitoring Extn
18th May 20224:36 pmRNSPrice Monitoring Extension
12th May 20223:58 pmRNSDirector/PDMR Shareholding
11th May 20222:13 pmRNSDirector/PDMR Shareholding
25th Apr 20225:16 pmRNSDirector/PDMR Shareholding
25th Apr 20227:00 amRNS2021 Annual Report and Notice of the 2022 AGM
11th Apr 20223:49 pmRNSDirector/PDMR Shareholding
22nd Mar 20227:00 amRNSPreliminary Results
14th Mar 202212:30 pmRNSDirector/PDMR Shareholding
25th Feb 20227:00 amRNSNotice of results and investor presentation
15th Feb 20224:26 pmRNSDirector/PDMR Shareholding
27th Jan 20227:00 amRNSFull Year Trading Update
12th Jan 202211:12 amRNSDirector/PDMR Shareholding
23rd Dec 20211:56 pmRNSDirector/PDMR Shareholding
17th Dec 20217:00 amRNSTrading Update
14th Dec 202111:55 amRNSDirector/PDMR Shareholding
12th Nov 202112:41 pmRNSDirector/PDMR Shareholding
10th Nov 20215:48 pmRNSHolding(s) in Company
4th Nov 20215:59 pmRNSHolding(s) in Company
4th Nov 20213:31 pmRNSDirector/PDMR Shareholding
3rd Nov 20217:00 amRNSQ3 Trading Update
15th Oct 202112:10 pmRNSDirector/PDMR Shareholding
12th Oct 202111:05 amRNSDirector/PDMR Shareholding
1st Oct 20213:31 pmRNSHolding(s) in Company
14th Sep 202110:05 amRNSDirector/PDMR Shareholding
12th Aug 20212:28 pmRNSDirector/PDMR Shareholding
10th Aug 20217:00 amRNSInterim Results
19th Jul 20219:26 amRNSNotice of Results
13th Jul 20211:59 pmRNSDirector/PDMR Shareholding
14th Jun 20213:06 pmRNSDirector/PDMR Shareholding
14th Jun 202111:35 amRNSDirector/PDMR Shareholding
10th Jun 20214:41 pmRNSDirector/PDMR Shareholding
9th Jun 20213:48 pmRNSDirector/PDMR Shareholding
2nd Jun 20213:49 pmRNSHolding(s) in Company
26th May 202112:08 pmRNSResult of AGM
26th May 20217:00 amRNSTrading Update
12th May 20213:44 pmRNSDirector/PDMR Shareholding
28th Apr 20212:05 pmRNSDirector/PDMR Shareholding
26th Apr 20213:16 pmRNS2020 Annual Report, Notice of the 2021 AGM

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.